Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 177

Results For "C"

9533 News Found

Lupin to use Honeywell’s HFO technology in inhalers
News | May 21, 2025

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants


IICP and Indegene partner to enable more inclusive society
News | May 20, 2025

IICP and Indegene partner to enable more inclusive society

IICP is a registered charitable society working in the disability sector since 1974


Global Health posts Q4 FY25 consolidated PAT at Rs. 101.4 Cr
News | May 20, 2025

Global Health posts Q4 FY25 consolidated PAT at Rs. 101.4 Cr

Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025


Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali
News | May 20, 2025

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds


Zydus Wellness records a growth of 30% in net profit in FY25
News | May 20, 2025

Zydus Wellness records a growth of 30% in net profit in FY25

EBITDA for the period rose by 23.2% to Rs. 3,797 million


Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr
News | May 18, 2025

Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr

Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025


Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr
News | May 18, 2025

Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr

The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025


Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
News | May 18, 2025

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis


Briefs: Dr. Reddy's Laboratories, Relonchem,  Shilpa Pharma Lifesciences and Shanmuga Hospital
News | May 18, 2025

Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA